Intervention not reported
Ciprofloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 0.62 [0.12, 3.31]
Studies not reported
Very low
Intervention not reported
Sulfamethoxazole + trimethoprim (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole + trimethoprim (no direct RCT) (very low certainty).
1 finding from 1 review
HR 2.62 [0.62, 11.91]
Studies not reported
Very low
Intervention not reported
Rifaximin (2 RCTs, 106 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (2 RCTs, 106 participants) (very low certainty).
1 finding from 1 review
HR 7.8 [0.13, 4647.11]
Studies not reported
Very low
Intervention not reported
Norfloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.16 [0, 1.56]
Studies not reported
Very low
Intervention not reported
No active intervention · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Norfloxacin + neomycin (1 RCT, 22 participants) · people with liver cirrhosis
The intervention may leads to lower norfloxacin + neomycin (1 RCT, 22 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin + rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin + rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 575 participants) · people with liver cirrhosis
The intervention may leads to lower rifaximin (3 RCTs, 575 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (3 RCTs, 439 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 439 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 479 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 479 participants) (very low certainty).
1 finding from 1 review
HR 0.57 [0.33, 1]
Studies not reported
Very low
Intervention not reported
Norfloxacin (4 RCTs, 546 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (4 RCTs, 546 participants) (very low certainty).
1 finding from 1 review
HR 0.74 [0.49, 1.09]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.61 [0.31, 1.16]
Studies not reported
Very low
Intervention not reported
Sulfamethoxazole +trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole +trimethoprim (1 RCT, 60 participants) (very low certainty).
1 finding from 1 review
HR 0.47 [0.2, 1]
Studies not reported
Very low
Intervention not reported
Norfloxacin +rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin +rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 0.4 [0.12, 1.17]
Studies not reported
Very low
Intervention not reported
Rufloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes rufloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 1.45 [0.27, 8.21]
Studies not reported
Very low
Intervention not reported
Rifaximin (2 RCTs, 353 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (2 RCTs, 353 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Total postoperative infections ‐ early and late Urinary tract infection Pelvic infection Other serious infections Postoperative fever · women having elective vaginal hysterectomy
It is very uncertain whether the intervention changes total postoperative infections ‐ early and late Urinary tract… (very low certainty).
1 finding from 1 review
Intervention not reported
Total adverse effects · women having elective vaginal hysterectomy
1 finding from 1 review
Intervention not reported
Total postoperative infections ‐ early and late Abdominal wound infection Urinary tract infection Pelvic infection Other serious infections Postoperative fever · women having elective abdominal hysterectomy
1 finding from 1 review
Intervention not reported
Total adverse effects · women having elective abdominal hysterectomy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found